Several of these alterations are clinically actionable: in particular, IDH1/2 mutations and FGFR2 fusions have led to the development of targeted therapies with a shift towards biomarker-driven treatment strategies in iCCA (Table 4). Here, FGFR2 is linked to infantile convulsions and choreoathetosis.